0222 GMT - CSL's U.S. agreements on drug pricing and manufacturing expansion remove two overhangs on the stock, Morgans analyst Derek Jellinek says. He tells clients in a note that the Australia-based pharmaceutical company has reinforced its competitive position as a major U.S. manufacturer of plasma-derived therapies. Jellinek sees the key positive of CSL's Medicaid pricing agreement as the improved visibility on exposure to potential U.S. drug-pricing reform. As for its onshoring agreement, he reckons it gives greater certainty with regard to tariff exposure. Morgans has a last-published buy rating on the stock and a target price of 187.71 Australian dollars. Shares are up 0.9% at A$173.07.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.